G
Gossamer Bio, Inc. (GOSS)
NMS – Real Time Price. Currency in USD
0.35
-0.03 (-7.55%)
At close: Mar 27, 2026, 4:00 PM EDT
0.36
+0.01 (3.58%)
After-hours: Mar 27, 2026, 7:03 PM EDT
Get all premium features to the best stock analysis tool
NMS – Real Time Price. Currency in USD
0.35
-0.03 (-7.55%)
At close: Mar 27, 2026, 4:00 PM EDT
0.36
+0.01 (3.58%)
After-hours: Mar 27, 2026, 7:03 PM EDT
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
| Name | Position |
|---|---|
| Dr. Richard Aranda M.D. | Chief Medical Officer |
| Dr. Robert F. Roscigno Ph.D. | Senior Vice President of Clinical Development of Pulmonary Vascular Disease |
| Mr. Bryan Giraudo | COO & CFO |
| Mr. Christian Waage J.D. | Executive Vice President of Technical Operations & Administration |
| Mr. Faheem Hasnain | Co-Founder, CEO, President & Chairman |
| Mr. Jeff Boerneke | General Counsel & Secretary |
| Mr. Matt Cravets | Senior Vice President of Biometrics |
| Date | Type | Document |
|---|---|---|
| 2026-03-17 | POSASR | a20260317-gossxposasr.htm |
| 2026-01-28 | S-3ASR | a20260128-gossxsx3asr.htm |
| 2025-11-05 | 8-K | goss-20251105.htm |
| 2025-09-25 | 8-K | goss-20250924.htm |
| 2025-08-05 | 8-K | goss-20250805.htm |
| 2025-06-25 | 8-K | goss-20250625.htm |
| 2025-06-16 | 8-K | goss-20250616.htm |
| 2025-05-15 | 10-Q | goss-20250331.htm |
| 2025-04-29 | DEF 14A | goss-20250429.htm |
| 2025-03-13 | 10-K | goss-20241231.htm |
| Ms. Caryn L. Peterson |
| Executive Vice President of Regulatory Affairs |
| Ms. Deanna Weber | Executive Vice President of Human Resources |
| Ms. Jeanine Anthony | Senior Vice President of Marketing |